Incensole + incensole acetate in the AromaForge archive is a grouped frankincense marker record rather than one purified molecule. The strongest live evidence supports identity, Boswellia occurrence, and analytical usefulness: accessible sources repeatedly treat incensole and its acetate as characteristic cembrane diterpenes of frankincense, especially B. papyrifera and some B. carterii material. The pharmacology literature is materially stronger for incensole acetate than for incensole itself, so this combined record should present the acetate-driven TRPV3, NF-kappaB, and neuroprotection findings clearly while warning that those results do not automatically transfer to every combined GC peak or to the free alcohol alone.
Chemical identity and composition
This record exists because some archive oil profiles and external reports discuss incensole and incensole acetate together as a frankincense marker pair. They are related but distinct compounds: incensole is the free diterpene alcohol (CAS 22419-74-5) and incensole acetate is its acetate ester (CAS 34701-53-6). A 2012 HPLC paper describes both as typical biomarkers for B. papyrifera, while broader Boswellia and authentication literature uses them as part of frankincense chemotaxonomy and adulteration control.
Aroma and practical use
- Use the recorded resinous, balsamic, warm, incense-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2008 mouse and cell study reported that incensole acetate acted as a potent TRPV3 agonist and produced anxiolytic-like and antidepressive-like behavioral effects in wild-type but not TRPV3-knockout mice.
This is the best-known frankincense cembrane paper, but it is acetate-specific preclinical evidence and should not be translated into human mood claims.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2007 bioassay-guided fractionation study isolated both incensole acetate and incensole from Boswellia resin and found that incensole acetate inhibited NF-kappaB pathway activation and showed anti-inflammatory activity in a mouse inflamed paw model.
This finding supports the pair's relevance to frankincense pharmacology, but the in vivo anti-inflammatory result was centered on incensole acetate.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2012 mouse ischemia paper reported that post-ischemia incensole acetate reduced infarct volume, improved neurological activity, lowered inflammatory cytokine expression, and retained a treatment window up to 6 hours in the tested model.
This is still animal neuroprotection work, but it is one of the stronger follow-up papers showing the frankincense cembrane scaffold was studied beyond a single screening experiment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2012 HPLC paper described both incensole and incensole acetate as typical biomarkers for B. papyrifera and presented a quantification method for the pair in frankincense extracts.
This is useful identity and sourcing support for the combined record because it directly treats the two molecules as a recognizable Boswellia marker set.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No standalone human safety dossier or IFRA use limit was verified for the combined incensole plus incensole acetate analytical label.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The accessible Good Scents trade pages for both incensol and incensyl acetate show no on-page GHS classification and mark them as not for fragrance or flavor use, but those entries are not substitutes for formal toxicology review.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the literature is preclinical and chemically split between the free alcohol and the acetate ester, safety interpretation should remain chemistry-first and avoid implying validated consumer-wellness use.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
trpv3_agonism_by_incensole_acetate
A 2008 FASEB Journal paper identified incensole acetate as a potent TRPV3 agonist in brain-linked preclinical systems and linked the behavioral effects to TRPV3-dependent signaling.
This experimental finding does not establish benefit, dose or safety in people using this blend.
nf_kappab_pathway_suppression_by_incensole_acetate
A 2007 Mol Pharmacol paper reported that incensole acetate inhibited TAK/TAB-mediated IKK activation loop phosphorylation, reducing cytokine- and lipopolysaccharide-mediated NF-kappaB activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- This record is an analytical grouping, so it does not have a single CAS number or a single standalone toxicology dossier.
- Most constituent-specific mechanistic and animal evidence in the accessible literature is for incensole acetate, not for the grouped pair.
- Public fragrance-use guidance for these frankincense cembranes remains sparse compared with better-studied aroma chemicals.
- No IFRA Standard or RIFM safety assessment was found for incensole or incensole acetate in this pass; the previously listed 0.1% dermal limit was an uncited placeholder and has been removed pending real safety data.
- Second-pass 2026-07-13 retry tried two different angles: (1) a direct CAS search on '22419-74-5' and '34701-53-6' against IFRA/RIFM, which returned only supplier/identity/SDS listings (ChemicalBook, Chemdor SDS, Sigma-Aldrich, Caymanchem, PubChem) and no IFRA Standard or RIFM assessment; (2) a Tisserand & Young Essential Oil Safety 2nd ed. search for frankincense/incensole, which found that Tisserand & Young classify frankincense oils (B. carterii/B. sacra) as GRAS for topical use at up to 2% in leave-on products, but this is a whole-essential-oil guideline, not a constituent-specific dermal limit for isolated incensole or incensole acetate, so it cannot be used to populate this record's compound-level dermal_limit_pct. Fields remain null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.